APAC Peptic Ulcer Drugs Market

APAC Peptic Ulcer Drugs Market Size (2023 to 2028)

The APAC peptic ulcer drugs market is anticipated to be worth USD 1.41 bn by 2028 from USD 1.13 bn in 2023, growing at a CAGR of 4.5% from 2023 to 2028.

The growing population suffering from peptic ulcers in Asia-Pacific countries primarily propels market growth. Peptic ulcers occur in the gastrointestinal system when gastric acid and pepsin levels increase in the stomach. The market is also being driven by the increasing demand from the aging population, particularly those over 55 years of age who are using a variety of medications. Moreover, individuals with peptic ulcer disease may also suffer from chronic kidney diseases. These factors indicate a potential growth opportunity for businesses operating in the peptic ulcer treatment market.

Changes in lifestyles and the widespread use of advanced technologies further contribute to the growth rate of the APAC peptic ulcer drugs market. The rise in alcohol consumption and smoking is particularly noteworthy as it contributes significantly to the prevalence of peptic ulcer disorder. According to a recent survey, tobacco usage stands at approximately 267 million users globally, with over 100 million individuals above the age of 15 using cigarettes and bidis. Nicotine, which is present in tobacco and cigarettes, can diminish the generation of prostaglandin in the gastric mucosa of smokers, leading to ulceration. Consequently, there is a growing demand for peptic ulcer drugs among these individuals, presenting a potential market opportunity for businesses operating in this space.

The growing support from governments of Asia-Pacific countries and increasing R&D efforts from the market participants further boost regional market growth. The rising demand for peptic ulcer drugs has resulted in significant investment by key players and pharmaceutical companies in the development of various forms of drugs, including pills, syrups, and powders. This has been further facilitated by increasing research and development activities, favorable government policies and regulations, and growing investment in healthcare infrastructure. Such factors are anticipated to favor the market and help register a healthy CAGR during the forecast period.

Side effects associated wtih the prolonged usage of peptic ulcer drugs such as headache, vomiting, diarrhea and constipation are one of the major factors hampering the regional market growth. In addition, the lack of availability of ulcer drugs in offline pharmacies in a few rural areas, lack of awareness about the drugs and long-time approval for novel drugs further hinder the peptic ulcer drugs market growth in the Asia-Pacific region.

This research report on the APAC peptic ulcer drugs market has been segmented and sub-segmented into the following categories:

By Drug Type:

• Proton Pump Inhibitors (PPIs)
• Anti-Histamines
• H2 Antagonists
• Antacids
• Antibiotics
• Others

By Ulcer Type:

• Gastric Ulcers
• Duodenal Ulcer
• Esophageal Ulcer

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand, Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, the Asia-Pacific had a considerable share of the worldwide market in 2022 and is anticipated to grow at the fastest CAGR during the forecast period. China accounted for the largest share of the APAC market in 2022 and is expected to grow at a promising pace during the forecast period. The growth of the Chinese market is majorly driven by factors such as the growing number of R&D activities on peptic ulcer drugs by the market participants and research centers and encouragement from the Chinese government.

The Indian market is anticipated to register a prominent CAGR during the forecast period. The growing number of hospitals and clinics for stomach ulcer treatment and an increasing number of approvals for peptic ulcer drugs boost the Indian market growth. In addition, growing awareness among the Indian population regarding peptic ulcers, the increasing aging population suffering from peptic ulcers and growing healthcare expenditure further boost the growth rate of the Indian market.

Japan is another noteworthy regional market for peptic ulcer drugs in Asia-Pacific and is anticipated to account for a considerable share of the APAC market during the forecast period.

KEY MARKET PLAYERS:

Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc., Helicure AB and Eumedica Pharmaceuticals are some of the companies currently dominating the APAC peptic ulcer drugs market and profiled in this report.